Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
Fiche publication
Date publication
décembre 2020
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Extraintestinal manifestations (EIMs) are frequent in patients with inflammatory bowel diseases (IBD) and a challenging condition to manage. Tumor necrosis factor alpha antagonists (anti-TNFα) are recognized as the primary therapeutic option. We aimed to summarize evidence on the efficacy of ustekinumab for the treatment of EIMs.
Mots clés
Crohn disease, Inflammatory bowel diseases, extra-intestinal manifestations, ulcerative colitis, ustekinumab
Référence
J Crohns Colitis. 2020 Dec 24;: